TEA-ACLF: Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study

Sponsor

RenJi Hospital (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05036031

Collaborator

(none)

500

Enrollment

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The definition and diagnostic criteria of acute-on chronic liver failure (ACLF) differed evidently between the East and the West due to the difference in the underlying etiology. Liver transplantation is the most effective treatment to reverse the progress of ACLF and improve the survival rate of patients. The purpose of this study is to explore the accuracy of the two diagnostic criteria of EASL-CLIF and APASL ACLF in assessing the survival rate of patients with liver cirrhosis after LT.

Condition or Disease	Intervention/Treatment	Phase
Acute-On-Chronic Liver Failure Liver Cirrhosis Liver Transplant; Complications

Detailed Description

A retrospective collection and analysis of the preoperative conditions of patients with LT due to cirrhosis in a single center from January 2015 to June 2020 would be conducted, including epidemiological characteristics, etiology, clinical indicators, and short-term (28 days, 90 days) and long-term (1 year, 3 years) survival after LT.

Study Design

Study Type:

Observational

Anticipated Enrollment :

500 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

Liver Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study to Evaluate Different Criterion in Predicting Post-transplant Outcomes

Anticipated Study Start Date :

Sep 1, 2021

Anticipated Primary Completion Date :

Oct 1, 2021

Anticipated Study Completion Date :

Oct 31, 2021

Arms and Interventions

Arm	Intervention/Treatment
EASL-CLIF ACLF patients
APASL ACLF patients
Non-ACLF patients

Outcome Measures

Primary Outcome Measures

3 years overall survival [Up to ~3 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 80 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

patients underwent liver transplantation for cirrhosis
The diagnosis of ACLF followed APASL and EASL-CLIF definition.

Exclusion Criteria:

Patients with malignant tumor or underwent living donor liver transplantation (LDLT) were excluded.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

RenJi Hospital

Investigators

Study Chair: Qiang Xia, Dept. Liver Surgery, Renji Hospital, School of Medicine, SJTU
Principal Investigator: Hao Feng, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University